Ekso Bionics Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements - Change in Level 3 (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Loss on revaluation of warrants issued in conjunction with 2015 financing	$ (1,122)	$ 732
Loss on modification of warrants	257	$ 0
Warrant Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning Balance	585
Loss on revaluation of warrants issued in conjunction with 2015 financing	1,122
Loss on modification of warrants	257
Loss on revaluation of contingent liability	0
Ending Balance	1,964
Contingent Success Fee Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning Balance	34
Loss on revaluation of warrants issued in conjunction with 2015 financing	0
Loss on modification of warrants	0
Loss on revaluation of contingent liability	1
Ending Balance	$ 35